|
| Author, country, year | Sample size | Study design | CI-AKI patients number | Inclusion criteria | Age, years N/C | Male N/C | SCr baseline N/C mmol/L | CI-AKI criteria | Hypertension % N/C | DM% N/C | CM type |
|
| Wybraniec et al., Poland, 2017 [22] | 95 | Prospective | 9 | Normal sCr | 64 (52–75) | 52 (54.4%) | 70.72 (60.99–82.21) | ≥50% relative or ≥0.3 mg/dL absolute increase of serum creatinine concentration at 48 h postprocedurally | 48 (50.4%) | 17 (17.6%) | Iopromide (LOCM) or Iodixanol (IOCM) or Iomeprol (LOCM) |
| Akdeniz et al., Turkey, 2015 [8] | 52 | Nested case-control | 32 | Normal sCr | 67.5 ± 10.1/61.6 ± 9.4 | 11(34.4)/12(60.0) | 79.56(44.2–167.96) | An increase in sCr by 0.3 mg/dL from a baseline level according to the KDIGO 2012 AKI criteria | -/0.5 | 81.3/85 | Iodixanol |
| Li et al., China, 2015 [9] | 145 | Prospective | 19 | eGFR > 15 mL/min/1.73 m2 | 66.8 ± 9.9 | 91(62.8) | 70.58 ± 9.9/60.41 ± 14.20 | An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24–48 h after the intravascular injection of contrast medium, without an alternative etiology | NR | NR | Nonionic, low osmolarity contrast agent |
| Luo et al., China, 2013 [18] | 42 | Nested case-control | 12 | sCr < 1.5 mg/dL in male/sCr < 1.2 mg/L in female | 68.4 ± 10.1/64.7 ± 13.2 | 5(41.7)/12(40.0) | 68.76 ± 10.92/66.57 ± 12.89 | An absolute rise in sCr of ≥0.5 mg/dl (44.2 mmol/l), and/or a ≥25% increase from the baseline within 48 hours | 58.3/56.7 | NR | Nonionic, low osmolarity contrast medium (iopamidol) |
| Torregrosa et al., Spain, 2015 [19] | 144 | Prospective | 20 | eGFR > 15 mL/min/1.73 m2 | 72 ± 10/62 ± 13 | 16(75)/94(75.8) | 78.68 ± 21.22/100.78 ± 23.87 | An increase in sCr ≥ 50 % according to the RIFLE classification system | NR | NR | NR |
| Vijayasimha et al., India, 2014 [17] | 100 | Prospective | 12 | sCr < 1.5 mg/dL in male/sCr < 1.2 mg/Ll in female | 48.6 ± 11 | 62(62) | 106.09 ± 15.03 | An increase in sCr >25% of the baseline level 48 hours after contrast | NR | NR | Low osmolarity contrast (iodizanol or iopromide) medium. |
| Wang et al., China, 2014 [10] | 42 | Prospective | 14 | eGFR >15 mL/min/1.73 m2 | 60.2 ± 9.5/60.6 ± 8.1 | 7(50)/16(57) | 82.2 ± 18.3/92.0 ± 15.5 | An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24–48 h after the intra- vascular injection of contrast medium, without an alternative etiology | 64/60 | 14/17 | A nonionic, low osmolarity contrast agent 844 mOsm/kg |
| Wang, China, 2013 [21] | 260 | Prospective | 20 | sCr < 300 mmol/L | 73.6 ± 8.9/60 ± 7.5 | 8(40)/135(56.3) | 71.31 ± 8.3/65.7 ± 10.3 | An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24–48 h after the intravascular injection of contrast medium, without an alternative etiology | 50/20 | 15/5 | a nonionic, low osmolarity contrast agent 600 mOsm/kg |
| Wang, China, 2014 [20] | 66 | Prospective | 6 | eGFR < 60 mL/min/1.73 m2 | NR | NR | NR | An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24–48 h after the intravascular injection of contrast medium, without an alternative etiology | NR | NR | NR |
|
